Grupo Espanol De Tumores Neuroendocrinos

This study looked back at medical records of 19 Spanish patients with rare NTRK fusion cancers who received larotrectinib through a compassionate use program. Researchers wanted to see how well the drug worked and how long responses lasted. The goal is to gather real-world eviden…